NASDAQ$EWTX
Edgewise Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year 2023 and recent business highlights.
Edgewise Therapeutics reported fourth-quarter financial results, with R&D expenses at $27.7 million and G&A expenses at $6.2 million. The net loss for the quarter was $30.1 million, or $0.47 per share. The company's cash, cash equivalents, and marketable securities totaled approximately $318.4 million as of December 31, 2023, excluding $231.8 million in net proceeds from a January 2024 underwritten offering.
- Advanced the global pivotal cohort, GRAND CANYON, of EDG-5506 in Becker muscular dystrophy (Becker).
- Advanced Phase 2 LYNX trial of EDG-5506 including new cohort for boys with Duchenne muscular dystrophy (Duchenne) not currently treated with corticosteroids.
- Initiating Phase 2 FOX trial in boys with Duchenne who have been previously treated with gene therapy.
- Advanced Phase 1 trial of EDG-7500, a novel cardiac sarcomere modulator for hypertrophic cardiomyopathy (HCM), and other serious diseases of cardiac diastolic dysfunction.
Headline financials
Revenue & EPS history
Edgewise Therapeutics · Revenue · Quarterly
$2.25M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-0.2%
Avg return
Earnings day
+0.7%
Avg return
5 days after
-4.0%
Avg return
30 days after
40%
8 / 20 earnings
Positive
+16.0%
Q2 2022
Best reaction
-12.3%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.7% | -4.3% | +2.4% | |
| Q3 2025 | -1.7% | +23.7% | +35.8% | |
| Q2 2025 | -4.1% | -0.9% | +15.2% | |
| Q1 2025 | +2.4% | +1.0% | +5.8% | |
| Q4 2024 | -2.4% | +7.0% | -40.7% | |
| Q3 2024 | -0.7% | -3.9% | -11.0% | |
| Q1 2024 | -12.3% | -16.5% | -15.5% | |
| Q4 2023 | -1.3% | -3.7% | -7.1% | |
| Q3 2023 | -10.7% | +5.5% | +13.0% | |
| Q2 2023 | +3.4% | +12.5% | -3.4% | |
| Q1 2023 | -6.5% | -5.5% | -2.8% | |
| Q4 2022 | -3.0% | -2.8% | -30.3% | |
| Q3 2022 | +1.8% | +2.1% | -5.7% | |
| Q2 2022 | +16.0% | +6.8% | +17.1% | |
| Q1 2022 | +1.6% | -0.8% | -18.9% | |
| Q4 2021 | +13.0% | -2.5% | -19.3% | |
| Q3 2021 | -1.8% | -3.4% | -3.1% | |
| Q2 2021 | -5.6% | -10.6% | -7.9% | |
| Q1 2021 | +5.2% | +4.7% | -1.6% | |
| Q4 2020 | +5.2% | +4.7% | -1.6% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro